Peringatan Keamanan

Safety data are limited, however, headache, fatigue, diarrhea, nausea, vomiting, and abdominal pain have been reported commonly with the use of vapreotide.

Vapreotide

DB04894

biotech experimental investigational

Deskripsi

Vapreotide is a synthetic octapeptide somatostatin analog. It was being studied for the treatment of cancer.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) 30 minutes
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Vapreotide is 76% eliminated in bile. The remainder is renally eliminated.

Interaksi Obat

235 Data
Lomitapide The metabolism of Lomitapide can be decreased when combined with Vapreotide.
Bromocriptine The serum concentration of Bromocriptine can be increased when it is combined with Vapreotide.
Pegvisomant The risk or severity of increased transaminases can be increased when Vapreotide is combined with Pegvisomant.
Eliglustat The metabolism of Eliglustat can be decreased when combined with Vapreotide.
Ibrutinib The metabolism of Ibrutinib can be decreased when combined with Vapreotide.
Cilostazol The metabolism of Cilostazol can be decreased when combined with Vapreotide.
Colchicine The metabolism of Colchicine can be decreased when combined with Vapreotide.
Iloperidone The metabolism of Iloperidone can be decreased when combined with Vapreotide.
Retapamulin The metabolism of Retapamulin can be decreased when combined with Vapreotide.
Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Vapreotide.
Vardenafil The metabolism of Vardenafil can be decreased when combined with Vapreotide.
Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Vapreotide.
Zopiclone The metabolism of Zopiclone can be decreased when combined with Vapreotide.
Lovastatin The metabolism of Lovastatin can be decreased when combined with Vapreotide.
Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Vapreotide.
Alprazolam The metabolism of Alprazolam can be decreased when combined with Vapreotide.
Warfarin The serum concentration of Warfarin can be increased when it is combined with Vapreotide.
Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Vapreotide.
(R)-warfarin The serum concentration of (R)-warfarin can be increased when it is combined with Vapreotide.
R,S-Warfarin alcohol The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Vapreotide.
S,R-Warfarin alcohol The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Vapreotide.
(S)-Warfarin The serum concentration of (S)-Warfarin can be increased when it is combined with Vapreotide.
Midazolam The serum concentration of Midazolam can be increased when it is combined with Vapreotide.
Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Vapreotide.
Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Vapreotide.
Cyclosporine The bioavailability of Cyclosporine can be decreased when combined with Vapreotide.
Dotatate gallium Ga-68 Vapreotide may decrease effectiveness of Dotatate gallium Ga-68 as a diagnostic agent.
Lutetium Lu 177 dotatate The therapeutic efficacy of Lutetium Lu 177 dotatate can be decreased when used in combination with Vapreotide.
Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Vapreotide.
Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Vapreotide.
Azithromycin The metabolism of Azithromycin can be decreased when combined with Vapreotide.
Ziprasidone The metabolism of Ziprasidone can be decreased when combined with Vapreotide.
Chlorpromazine The metabolism of Chlorpromazine can be decreased when combined with Vapreotide.
Albendazole The metabolism of Albendazole can be decreased when combined with Vapreotide.
Cephalexin The metabolism of Cephalexin can be decreased when combined with Vapreotide.
Doxazosin The metabolism of Doxazosin can be decreased when combined with Vapreotide.
Norethisterone The metabolism of Norethisterone can be decreased when combined with Vapreotide.
Fenofibrate The metabolism of Fenofibrate can be decreased when combined with Vapreotide.
Atazanavir The metabolism of Atazanavir can be decreased when combined with Vapreotide.
Rosuvastatin The metabolism of Rosuvastatin can be decreased when combined with Vapreotide.
Drospirenone The metabolism of Drospirenone can be decreased when combined with Vapreotide.
Allylestrenol The metabolism of Allylestrenol can be decreased when combined with Vapreotide.
Zuclopenthixol The metabolism of Zuclopenthixol can be decreased when combined with Vapreotide.
Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Vapreotide.
Lacosamide The metabolism of Lacosamide can be decreased when combined with Vapreotide.
Linagliptin The metabolism of Linagliptin can be decreased when combined with Vapreotide.
Vorapaxar The metabolism of Vorapaxar can be decreased when combined with Vapreotide.
Suvorexant The metabolism of Suvorexant can be decreased when combined with Vapreotide.
Netupitant The metabolism of Netupitant can be decreased when combined with Vapreotide.
Tasimelteon The metabolism of Tasimelteon can be decreased when combined with Vapreotide.
Nintedanib The metabolism of Nintedanib can be decreased when combined with Vapreotide.
Tenofovir alafenamide The metabolism of Tenofovir alafenamide can be decreased when combined with Vapreotide.
Dihydroergocornine The metabolism of Dihydroergocornine can be decreased when combined with Vapreotide.
Duvelisib The metabolism of Duvelisib can be decreased when combined with Vapreotide.
Gilteritinib The metabolism of Gilteritinib can be decreased when combined with Vapreotide.
9-aminocamptothecin The metabolism of 9-aminocamptothecin can be decreased when combined with Vapreotide.
Methylprednisone The metabolism of Methylprednisone can be decreased when combined with Vapreotide.
Dihydroergocristine The metabolism of Dihydroergocristine can be decreased when combined with Vapreotide.
Dihydroergocryptine The metabolism of Dihydroergocryptine can be decreased when combined with Vapreotide.
Medical Cannabis The metabolism of Medical Cannabis can be decreased when combined with Vapreotide.
Elexacaftor The metabolism of Elexacaftor can be decreased when combined with Vapreotide.
Fosaprepitant The metabolism of Fosaprepitant can be decreased when combined with Vapreotide.
Lefamulin The metabolism of Lefamulin can be decreased when combined with Vapreotide.
Tazemetostat The metabolism of Tazemetostat can be decreased when combined with Vapreotide.
Methysergide The metabolism of Methysergide can be decreased when combined with Vapreotide.
Meperidine The metabolism of Meperidine can be decreased when combined with Vapreotide.
Ebastine The metabolism of Ebastine can be decreased when combined with Vapreotide.
Terfenadine The metabolism of Terfenadine can be decreased when combined with Vapreotide.
Cisapride The metabolism of Cisapride can be decreased when combined with Vapreotide.
Isavuconazole The metabolism of Isavuconazole can be decreased when combined with Vapreotide.
Pretomanid The metabolism of Pretomanid can be decreased when combined with Vapreotide.
Pimavanserin The metabolism of Pimavanserin can be decreased when combined with Vapreotide.
Estetrol The metabolism of Estetrol can be decreased when combined with Vapreotide.
Infigratinib The metabolism of Infigratinib can be decreased when combined with Vapreotide.
Dofetilide The metabolism of Dofetilide can be decreased when combined with Vapreotide.
Theophylline The metabolism of Theophylline can be decreased when combined with Vapreotide.
Carbamazepine The metabolism of Carbamazepine can be decreased when combined with Vapreotide.
Sirolimus The metabolism of Sirolimus can be decreased when combined with Vapreotide.
Quinidine The metabolism of Quinidine can be decreased when combined with Vapreotide.
Phenprocoumon The metabolism of Phenprocoumon can be decreased when combined with Vapreotide.
Busulfan The metabolism of Busulfan can be decreased when combined with Vapreotide.
Pimozide The metabolism of Pimozide can be decreased when combined with Vapreotide.
Amiodarone The metabolism of Amiodarone can be decreased when combined with Vapreotide.
Aminophylline The metabolism of Aminophylline can be decreased when combined with Vapreotide.
Paclitaxel The metabolism of Paclitaxel can be decreased when combined with Vapreotide.
Dasatinib The metabolism of Dasatinib can be decreased when combined with Vapreotide.
Fosphenytoin The metabolism of Fosphenytoin can be decreased when combined with Vapreotide.
Digitoxin The metabolism of Digitoxin can be decreased when combined with Vapreotide.
Everolimus The metabolism of Everolimus can be decreased when combined with Vapreotide.
Dronedarone The metabolism of Dronedarone can be decreased when combined with Vapreotide.
Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Vapreotide.
Temsirolimus The metabolism of Temsirolimus can be decreased when combined with Vapreotide.
Idelalisib The metabolism of Idelalisib can be decreased when combined with Vapreotide.
Ceritinib The metabolism of Ceritinib can be decreased when combined with Vapreotide.
Tianeptine The metabolism of Tianeptine can be decreased when combined with Vapreotide.
Osimertinib The metabolism of Osimertinib can be decreased when combined with Vapreotide.
Ribociclib The metabolism of Ribociclib can be decreased when combined with Vapreotide.
Dacomitinib The metabolism of Dacomitinib can be decreased when combined with Vapreotide.
Alpelisib The metabolism of Alpelisib can be decreased when combined with Vapreotide.
Astemizole The metabolism of Astemizole can be decreased when combined with Vapreotide.

Target Protein

Somatostatin receptor type 2 SSTR2
Somatostatin receptor type 5 SSTR5
Substance-P receptor TACR1

Referensi & Sumber

Synthesis reference: Venkata Raghavendra Palle, Maheedhara Reddy Challa, "PROCESS FOR PREPARING VAPREOTIDE." U.S. Patent US20070111930, issued May 17, 2007.
Artikel (PubMed)
  • PMID: 12691930
    Sarr MG: The potent somatostatin analogue vapreotide does not decrease pancreas-specific complications after elective pancreatectomy: a prospective, multicenter, double-blinded, randomized, placebo-controlled trial. J Am Coll Surg. 2003 Apr;196(4):556-64; discussion 564-5; author reply 565.
  • PMID: 12952505
    Authors unspecified: Vapreotide: BMY 41606, RC 160, Sanvar. Drugs R D. 2003;4(5):326-30.
  • PMID: 16047258
    Norman P: Vapreotide (Debipharm). IDrugs. 2000 Nov;3(11):1358-72.
  • PMID: 7909563
    Betoin F, Ardid D, Herbet A, Aumaitre O, Kemeny JL, Duchene-Marullaz P, Lavarenne J, Eschalier A: Evidence for a central long-lasting antinociceptive effect of vapreotide, an analog of somatostatin, involving an opioidergic mechanism. J Pharmacol Exp Ther. 1994 Apr;269(1):7-14.
  • PMID: 1354449
    Girard PM, Goldschmidt E, Vittecoq D, Massip P, Gastiaburu J, Meyohas MC, Coulaud JP, Schally AV: Vapreotide, a somatostatin analogue, in cryptosporidiosis and other AIDS-related diarrhoeal diseases. AIDS. 1992 Jul;6(7):715-8.
  • PMID: 7511473
    Stiefel F, Morant R: Vapreotide, a new somatostatin analogue in the palliative management of obstructive ileus in advanced cancer. Support Care Cancer. 1993 Jan;1(1):57-8.
  • PMID: 7912964
    Betoin F, Eschalier A, Duchene-Marullaz P, Lavarenne J: Seven-day antinociceptive effect of a sustained release vapreotide formulation. Neuroreport. 1994 Jan 31;5(5):642-4.

Contoh Produk & Brand

Produk: 0 • International brands: 3
International Brands
  • Octastatin
  • Sanvar
  • Sanvar IR

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul